$0.43
−3.15%Oct 27, 2026, 13:30 UTC
ONCOLYTICS BIOTECH INC reported GOBLET study data showing that all responding anal cancer patients survived for longer than one year.
Source:Oct 20, 2026, 13:35 UTC
ONCOLYTICS BIOTECH INC announced that it is presenting a trial-in-progress abstract and e-poster on the REO 033 study at the ESMO Congress 2026.
Source:Oct 14, 2026, 13:30 UTC
Oncolytics Biotech said it expects to receive the final payment under its grant from the Pancreatic Cancer Action Network, Inc. later in the fourth quarter of 2026.
Source:Oct 12, 2026, 20:05 UTC
ONCOLYTICS BIOTECH INC said it expects to add a composition-of-matter patent covering a modified next-generation pelareorep, extending protection for specified uses and future innovations into the late 2040s, subject to issuance and applicable patent terms.
Source:Oct 12, 2026, 20:05 UTC
ONCOLYTICS BIOTECH INC reported that three patent applications are pending, including two method-of-use applications, and said one is expected to be converted to a Track One application this quarter.
Source:Oct 12, 2026, 20:05 UTC
ONCOLYTICS BIOTECH INC said a new method-of-use patent covering pelareorep as a cancer immunotherapy has been issued in several countries, with U.S. issuance expected soon.
Source:Sep 29, 2026, 13:30 UTC
Oncolytics Biotech announced that data published in the Proceedings of the National Academy of Sciences show pelareorep converts immunologically inactive liver cancer tumors into immunologically active ones potentially susceptible to immunotherapy.
Source:Sep 10, 2026, 12:15 UTC
Oncolytics Biotech announced positive preclinical results for pelareorep combined with a pan-RAS inhibitor in a RAS-driven colorectal cancer model.
Source:Jun 2, 2026, 00:00 UTC
Oncolytics Biotech Inc. appointed Stephen Glover as a director, with an option to purchase 96,000 shares vesting over three years.
Jun 2, 2026, 00:00 UTC
Oncolytics Biotech Inc. appointed John McAdory as Chief Operating Officer, effective June 1, 2026.